Welcome to our dedicated page for Avita Medical SEC filings (Ticker: RCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AVITA Medical's SEC filings document its therapeutic acute wound-care business, RECELL-related commercial activity, operating results, capital structure, and corporate governance. Form 8-K reports include quarterly and annual financial results, material definitive agreements, credit-facility amendments and refinancing activity, leadership appointments, and board-structure changes.
Proxy materials describe annual meeting matters such as director elections, auditor ratification, non-executive director compensation, equity-award approvals, and governance requirements tied to the company's U.S. listing and ASX-related matters. The filings also provide formal disclosure around debt obligations, subsidiary guarantees, shareholder voting items, executive compensation arrangements, and risk areas affecting AVITA Medical's wound-care operations.
AVITA Medical, Inc. describes the issuance of a warrant connected to its existing five-year senior secured credit facility of up to $60 million with Perceptive Credit Holdings V, LP. The facility includes $50 million available at closing and an additional $10 million available by March 31, 2027, subject to a net revenue requirement.
Under this arrangement, AVITA issued a warrant to Perceptive to purchase up to 500,000 shares of common stock at an exercise price of $3.4019 per share, following stockholder approval at the 2026 Annual Meeting. If the additional $10 million commitment is drawn, a further 150,000 shares become issuable under the same warrant terms.
The shares underlying the warrant will be registered under AVITA’s Registration Statement on Form S-3 (File No. 333-294790), supported by a prospectus supplement filed on June 5, 2026. A legal opinion from K&L Gates LLP regarding the validity of the warrant shares is filed as an exhibit, and the disclosure clarifies that this communication is not itself an offer or solicitation to sell those shares.
AVITA Medical is registering up to 650,000 shares of common stock issuable under a warrant issued to Perceptive Credit Holdings V, LP; 500,000 shares are currently exercisable and an additional 150,000 shares vest only if the Company closes on an Additional Commitment Amount. The Warrant has an exercise price of $3.4019 per share and, if fully cashed-in, could provide the Company with up to approximately $2.2 million of proceeds. The exercise may be paid in cash or by withholding shares (including automatic cashless exercise mechanics), and the exercise window runs to the tenth anniversary of issuance. The registration covers shares issuable upon exercise of the Warrant and notes that the Company will bear registration costs; share issuance could be limited by ASX listing rules but such issuance was approved by stockholders on June 3, 2026.
AVITA Medical, Inc. director Woody Joseph Fralin reported buying a total of 10,000 shares of the company’s Common Stock in open-market transactions. The purchases on June 3, 2026 were made at prices of $4.0899 and $4.0999 per share.
After these trades, Fralin directly holds 92,761 shares of AVITA Medical common stock, which the disclosure notes includes unvested restricted stock units (RSUs). These are straightforward open-market purchases, increasing his direct equity stake in the company.
AVITA Medical, Inc. director Robert McNamara reported receiving new equity compensation. He was granted 22,214 restricted stock units, each representing one share of common stock, subject to time-based vesting. These RSUs vest 12 months after the January 20, 2026 grant date, following stockholder approval obtained on June 3, 2026.
McNamara was also granted 16,133 stock options to buy common stock at an exercise price of $3.77 per share. The options were approved by the board on January 5, 2026, have a grant date of January 20, 2026, become exercisable starting January 20, 2027, and expire on January 20, 2036. Following these awards, he directly owns 108,985 shares of common stock, including unvested RSUs.
AVITA Medical, Inc. granted equity awards to director Woody Joseph Fralin. On January 5, 2026, he received 40,547 restricted stock units (RSUs) and 29,446 stock options with a $3.47 exercise price, subject to stockholder approval obtained on June 3, 2026. On January 20, 2026, he received an additional 22,214 RSUs and 16,133 stock options with a $3.77 exercise price. The RSUs vest over time, and the options vest in three equal annual installments, providing long-term, stock-based compensation. Following these awards, his direct common stock holdings increased to 82,761 shares.
AVITA Medical, Inc. director Michael E. Tarnoff reported equity awards in the form of restricted stock units (RSUs) and stock options. On August 6, 2025, he received 26,250 RSUs and 19,063 stock options with an exercise price of $5.36 per share, vesting in three equal annual installments after the first anniversary. On January 20, 2026, he received an additional 22,214 RSUs that vest 12 months after the grant date and 16,133 stock options with an exercise price of $3.77 per share, also vesting in three equal annual installments beginning one year after grant. These awards were approved by the Board and were subject to stockholder approval obtained on June 3, 2026. Following the most recent RSU grant, Tarnoff directly holds 48,464 shares of common stock.
AVITA Medical, Inc. director Jeremy Curnock Cook reported equity awards consisting of restricted stock units and stock options granted as part of his compensation. He received 22,214 RSUs, each representing one share of common stock, which are subject to time-based vesting 12 months after the January 20, 2026 grant date and were approved by stockholders on June 3, 2026. He also received options to acquire 16,133 shares of common stock at an exercise price of $3.77 per share, exercisable starting January 20, 2027 and expiring January 20, 2036. Following the RSU award, his direct common stock holdings, including unvested RSUs, total 62,050 shares, and he holds 16,133 stock options.
AVITA Medical, Inc. director Suzanne Crowe reported equity awards granted as part of her compensation. She received 22,214 restricted stock units, each representing one share of common stock, which vest 12 months after the January 20, 2026 grant date, subject to previously obtained stockholder approval. She was also granted 16,133 stock options to buy common stock at an exercise price of $3.77 per share, exercisable until January 20, 2036. Following these awards, her direct holdings total 69,148 shares of common stock, which include unvested RSUs and 22,990 CHESS Depositary Interests that translate into 4,598 of these shares.
AVITA Medical, Inc. director Jan Stern Reed reported equity awards consisting of restricted stock units and options. Reed received 22,214 restricted stock units, each representing one share of common stock, that vest 12 months after the January 20, 2026 grant date and were subject to stockholder approval obtained on June 3, 2026.
On the same grant date, Reed was also granted 16,133 stock options to buy 16,133 shares of common stock at an exercise price of $3.77 per share, with an expiration date of January 20, 2036, also approved by stockholders on June 3, 2026. Following the equity award, Reed directly holds 73,225 shares of common stock, including unvested RSUs.
AVITA Medical, Inc. reported results of its 2026 annual stockholder meeting held by webcast. Of 30,776,689 common shares outstanding as of April 9, 2026, holders of 15,592,447 shares were represented, meeting quorum requirements.
Stockholders elected all seven director nominees and ratified Grant Thornton LLP as independent auditor for the year ending December 31, 2026. They approved increasing the non-executive directors’ aggregate annual cash fee pool from US$750,000 to US$900,000 and backed annual equity grants of restricted stock units and stock options to non-executive directors.
Initial equity grants to directors Michael Tarnoff and Joseph Woody were approved, along with an advisory vote in favor of named executive officer compensation and a preference for holding say-on-pay votes every one year. Stockholders also approved issuing warrants covering up to 650,000 shares to Perceptive Credit Holdings V, LP under an existing credit agreement and authorized the potential issuance of additional equity securities of up to 10% of issued capital under ASX Listing Rule 7.1A.